EMA to review Sanofi’s potential treatment for type 1 diabetes

The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for oral treatment sotagliflozin, developed in partnership with Lexicon Pharmaceutical, which would would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus. 

Sotagliflozin is an investigational dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys process blood sugar (glucose).

Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi, says that the challenges of type 1 diabetes management prevent many patients from reaching their treatment goals, despite the recent advancements. He said there is a need for therapies to be used in addition to insulin to help people with type 1 diabetes better control their blood sugar. He noted that Sotagliflozin is the first SGLT-1/2 dual inhibitor to be accepted for regulatory review in Europe. “We look forward to working with the EMA through the review process to bring this potential treatment to patients,” he said.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.